Effect Of Child Niuhuang Qingxin Powder Combined With Oseltamivir Phosphate On Children With Influenza

Objective This study was based on the "Guide to the Diagnosis and Treatment of Influenza" issued by the Health and Planning Commission in 2011.The randomized controlled trial was conducted to investigate the clinical efficacy of the use of proprietary Chinese medicine Child Niuhuang Qingxin powder San combined with oseltamivir phosphate in the treatment of pediatric flu.At the same time,the adverse drug reactions were monitored to provide evidence-based medical evidence for the clinical diagnosis and treatment of pediatric influenza.Methods This study selected patients with suspected influenza cases of acute respiratory infection who were admitted to Wuhan General Hospital of the Chinese People’s Liberation Army from December 2016 to March 2017 and November 2017 to January 2018 to perform swabbing and rapid serum flu.Children with positive throat swab antigen detection and positive serology test results were diagnosed as influenza cases.In combination with the dialectical classification of TCM,influenza cases that met the heat-toxin-infected lung type were included in the study and others were excluded.All the guardians of the children who participated in the study signed the informed consent form and conducted the concept of diagnosis and treatment.All children were randomly divided into experimental and control groups using a random sampling method.The experimental group was treated with Child Niuhuang Qingxin powder and oseltamivir combination.The control group was given only oseltamivir.The treatment course was set to 5 Days,detailed records of each patient’s basic data(age,gender,etc.),history of influenza exposure,history of vaccination,and other epidemiological features;dynamic monitoring of vital signs and symptom changes;laboratory laboratory test results(Blood routine,myocardial enzymes,liver and kidney function,lymphocyte type,influenza virus antigen detection,etc.)were measured before and after treatment;adverse drug reactions were monitored at the same time,and scores were recorded quantitatively using the integral system.Use Excel to enter all collected data to create a database and perform statistical analysis using Spss17.0.Results 1.Basic data: In this study,157 cases of confirmed influenza cases were collected in total,which were in accordance with the 77 cases of TCM-pneumococcal lung disease.Two cases of serious adverse events occurred.One treatment program was terminated because of disease progression.The final experimental group of 36 cases,the control group of 38 cases.The average age was 6.7±3.2 years old,the minimum was 2 years old,and the maximum was 12 years old.45 males and 29 females were enrolled.18 people completed the vaccination history,43 had clear contact history.2.In terms of symptom relief: In fever,cough,sputum,nasal congestion,sore throat and other symptoms,the course of the experimental group was significantly shorter than the control group(P <0.01).;Febrile convulsion occurred in none of the children in the group,and 3 cases in the control group had febrile convulsion.The incidence was 7.89%.There was a significant difference between the two groups.3.In terms of symptom scores: Before treatment,there was no significant difference between the two groups in the scores of the symptom scores and total scores(P>0.05).After treatment,the scores of the experimental group and the control group decreased significantly(P<0.01).The scores in the experimental group decreased more significantly..The differences between the groups before and after treatment were significant.;the effective rate was 91.67% in the experimental group and 71.05% in the control group.The analysis was 0.01<P<0.05,and the difference was statistically significant;The effective rates of the two groups were 100% and 97.37% respectively,with no significant difference.4.In the laboratory examination: there was no significant change in WBC between the two groups before and after treatment.The percentage of lymphocytes(L%)in the two groups was significantly reduced before treatment,and there was no difference between groups.After treatment,L% returned to normal.There was a difference between groups.Before treatment,there were abnormalities in liver function,myocardial enzyme spectrum,and lymphocyte type in the two groups,but there was no significant difference between the two groups.After treatment,both groups basically returned to normal.The experimental group improved liver function and the T cell subsets compared with the control group.The difference was significant,and there was no difference in myocardial enzyme spectrum.After the treatment,32 cases of the virus in the experimental group were negatively retested,and 29 cases in the experimental group were negative.The rate of negative conversion in the two groups was 0.01<P<0.05,which was statistically significant.5.Safety: There were 2 cases of adverse events in the experimental group with an incidence rate of 5.56%,of which 2 cases were nausea,vomiting and dizziness respectively.In the control group,there were 3 cases of adverse reactions with an incidence rate of 7.89%,of which 2 cases were Nausea and vomiting,1 case of liver damage.The incidence of adverse reactions between the two groups was P>0.05.There was no significant difference in safety between the two treatment options.Conclusions The therapeutic effect of Niu Huang Qing Xin San combined with oseltamivir in the treatment of pediatric fever-infected lung flu is better than that of oseltamivir alone.The specific manifestation is that the combination of the two drugs is superior to the duration of antipyretic and respiratory symptoms.Oseltavir was used alone;when the two were combined,there was a higher recovery rate and markedly effective rate;and Child Niuhuang Qingxin powder combined with oseltamivir also had an effect on enhancing immune function in children with influenza,T cell subsets have clinical significance for the early identification of influenza and can be included in routine examinations to confirm suspected cases of influenza;two treatment options in terms of safety There is no obvious difference.It is recommended that the combination of these two drugs be used for the heat-toxic lung-type pediatric flu.The curative effect is significant,the duration of the disease is significantly shortened,and the safety is high.